Paper Details

  1. Home
  2. Paper Details

Beneficial effects of albuterol therapy driven by heliox versus by oxygen in severe asthma exacerbation.

Author: ChangHsueh-Wen, HsuChien-Wei, HuangYuh-Chin T, LeeDavid Lin, LeeHuan

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Two trials showed that heliox-driven albuterol therapy improved peak expiratory flow rate (PEF) and reduced emergency department (ED) stay in patients with severe asthma exacerbation. Older patients and those with lower pretreatment PEF benefited most.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To determine and define the beneficial effects of heliox-driven albuterol therapy on severe asthma exacerbation and clinical factors that affect greater response. METHODS: The authors conducted two randomized, double-blinded, controlled trials in patients with severe asthma exacerbation...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1197/j.aem.2005.04.020

データ提供：米国国立医学図書館（NLM）

Beneficial Effects of Albuterol Therapy Driven by Heliox Versus by Oxygen in Severe Asthma Exacerbation

Imagine struggling to breathe amidst a dense desert sandstorm – this is what a severe asthma exacerbation feels like! This research explores the effectiveness of using heliox, a mixture of helium and oxygen, as a delivery method for albuterol therapy in patients experiencing severe asthma exacerbations. The study aimed to compare the effects of heliox-driven albuterol therapy with oxygen-driven albuterol therapy on improving lung function and reducing symptoms in patients with severe asthma exacerbations.

Heliox-Driven Albuterol Therapy Shows Promising Results

The research found that heliox-driven albuterol therapy resulted in more rapid and significant improvements in lung function, as measured by peak expiratory flow rate (PEF), compared to oxygen-driven albuterol therapy. Additionally, patients receiving heliox-driven albuterol therapy tended to have shorter hospital stays. These findings suggest that heliox-driven albuterol therapy could be a valuable adjunct treatment option for patients with severe asthma exacerbations, particularly for older patients with lower pretreatment PEF. It's like finding a more efficient way to navigate a desert – heliox-driven albuterol therapy could help patients overcome the obstacles of severe asthma exacerbations more effectively.

A New Approach to Managing Severe Asthma Exacerbations

This research offers a promising new approach to managing severe asthma exacerbations, helping patients navigate the desert of airway inflammation and narrowing. It emphasizes the importance of considering individual factors, such as age and pretreatment PEF, when selecting the most effective treatment strategy. This research could lead to improved treatment outcomes and a more comfortable experience for patients with severe asthma exacerbations.

Dr.Camel's Conclusion

This research demonstrates the potential benefits of heliox-driven albuterol therapy for patients with severe asthma exacerbations. It's like finding a new path through the desert of asthma symptoms – a path that could lead to faster and more effective relief. This research provides a valuable tool for clinicians seeking to improve the treatment of severe asthma exacerbations.

Date :
  1. Date Completed 2006-03-10
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

16141015

DOI: Digital Object Identifier

10.1197/j.aem.2005.04.020

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.